Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2026 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 8.650-9.000 for the period, compared to the consensus earnings per share estimate of 8.020. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $103.12 on Friday. The stock has a market cap of $12.23 billion, a P/E ratio of 30.78, a P/E/G ratio of 0.36 and a beta of 0.85. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The stock’s fifty day moving average is $76.48 and its 200 day moving average is $71.47. Halozyme Therapeutics has a one year low of $61.22 and a one year high of $103.30.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 232.11% and a net margin of 24.86%.Halozyme Therapeutics’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts anticipate that Halozyme Therapeutics will post 7.54 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on HALO shares. UBS Group reiterated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and set a $110.00 price target on the stock in a report on Friday. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Morgan Stanley decreased their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Insider Activity

In related news, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $51,886,572.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 72,477 shares of company stock worth $5,102,643. 2.50% of the stock is currently owned by insiders.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
• Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
• Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
• Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HALO. Voloridge Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the third quarter valued at approximately $77,587,000. Qube Research & Technologies Ltd bought a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $51,295,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Halozyme Therapeutics by 29.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after buying an additional 749,484 shares during the period. Royal London Asset Management Ltd. raised its holdings in shares of Halozyme Therapeutics by 122.3% in the second quarter. Royal London Asset Management Ltd. now owns 1,101,912 shares of the biopharmaceutical company’s stock worth $57,321,000 after buying an additional 606,236 shares during the period. Finally, AQR Capital Management LLC lifted its stake in shares of Halozyme Therapeutics by 155.7% during the 3rd quarter. AQR Capital Management LLC now owns 968,511 shares of the biopharmaceutical company’s stock worth $71,031,000 after acquiring an additional 589,711 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.